The SUM-225CWN cell line is particularly interesting as it was derived from a nodule that grew at the mastectomy scar of a patient that was previously treated with extensive high grade ductal carcinoma in situ (DCIS, Comedo type). Not surprisingly, these cells were found to harbor an amplification and overexpression of the ERBB2 (HER2) oncogene, which is common in patients with high grade DCIS. These cells will form xenograft tumors when implanted into immunodeficient mice and the tumors also show the comedo pattern of high grade DCIS. Thus, this cell line is an excellent model of high grade DCIS that progressed to overt malignancy. These cells are highly sensitive to ERBB2 targeted drugs.
Okay, let’s delve more deeply into the SUM-225 cell line.
- Characteristics of the patient from which SUM-225 was derived
- The oncogene signatures of this cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- Functional-druggable signature for SUM-225 cells
- Differential drug sensitivity data from Heiser et al.
- Bibliography of published papers in which SUM-225 cells were used
- SUM-225 blog
Back to the SUM cell line Gateway Page
